secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2025-04-15T23:59:59+00:00
Accession:  0001654954-25-004265
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata's XYNGARI Phase 3 trial shows stat sig benefit at 4 weeks in moderate-to-severe acne
--------------------------------------------------------------------------------

- IGA treatment success: 11.9% XYNGARI vs 6.2% placebo (p<0.05) at week 4, after 4 weekly doses.
- Inflammatory lesion count mean change: -11.4 XYNGARI vs -8.6 placebo (p<0.001).
- Non-inflammatory lesion count mean change: -12.4 XYNGARI vs -8.8 placebo (p<0.001).
- Data support earlier positive week 12 topline results for all primary endpoints.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000165495425004265/0001654954-25-004265-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000165495425004265/drma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-25-004265

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer